Julie S Nielsen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12141924/publications.pdf

Version: 2024-02-01

430874 677142 2,000 23 18 22 citations h-index g-index papers 23 23 23 3411 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma. Journal of Clinical Investigation, 2022, 132, .	8.2	12
2	A library-based screening method identifies neoantigen-reactive T cells in peripheral blood prior to relapse of ovarian cancer. Oncolmmunology, 2018, 7, e1371895.	4.6	35
3	Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma. Oncolmmunology, 2017, 6, e1321184.	4.6	23
4	Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. PLoS ONE, 2016, 11, e0155189.	2.5	112
5	Personalized Immunotherapy Targeting the Cancer Mutanome. , 2016, , 426-433.		1
6	The cell surface mucin podocalyxin regulates collective breast tumor budding. Breast Cancer Research, 2016, 18, 11.	5.0	26
7	Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells. Clinical Cancer Research, 2016, 22, 2226-2236.	7.0	26
8	Podocalyxin enhances breast tumor growth and metastasis and is a target for monoclonal antibody therapy. Breast Cancer Research, 2015, 17, 46.	5.0	58
9	Surveillance of the Tumor Mutanome by T Cells during Progression from Primary to Recurrent Ovarian Cancer. Clinical Cancer Research, 2014, 20, 1125-1134.	7.0	144
10	Tumor-infiltrating B cells and T cells. Oncolmmunology, 2012, 1, 1623-1625.	4.6	77
11	CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27â´´ Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian Cancer. Clinical Cancer Research, 2012, 18, 3281-3292.	7.0	447
12	An in vitro-transcribed-mRNA polyepitope construct encoding 32 distinct HLA class I-restricted epitopes from CMV, EBV, and Influenza for use as a functional control in human immune monitoring studies. Journal of Immunological Methods, 2010, 360, 149-156.	1.4	15
13	Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (αE/β7) Tj ETQq1 1	0.784314 1.4	rgBT Overlo
14	The Role of Podocalyxin in Health and Disease. Journal of the American Society of Nephrology: JASN, 2009, 20, 1669-1676.	6.1	179
15	Mammary tumors with diverse immunological phenotypes show differing sensitivity to adoptively transferred CD8+ T cells lacking the Cbl-b gene. Cancer Immunology, Immunotherapy, 2009, 58, 1865-1875.	4.2	9
16	CD34 is a Key Regulator of Hematopoietic Stem Cell Trafficking to Bone Marrow and Mast Cell Progenitor Trafficking in the Periphery. Microcirculation, 2009, 16, 487-496.	1.8	77
17	Novel functions of the CD34 family. Journal of Cell Science, 2008, 121, 3683-3692.	2.0	316
18	Tumor-Infiltrating T Cells Correlate with NY-ESO-1-Specific Autoantibodies in Ovarian Cancer. PLoS ONE, 2008, 3, e3409.	2.5	37

JULIE S NIELSEN

#	Article	IF	CITATION
19	Influence of host irradiation on long-term engraftment by CD34-deficient hematopoietic stem cells. Blood, 2007, 110, 1076-1077.	1.4	23
20	The CD34-Related Molecule Podocalyxin Is a Potent Inducer of Microvillus Formation. PLoS ONE, 2007, 2, e237.	2.5	71
21	Podocalyxin is a CD34-related marker of murine hematopoietic stem cells and embryonic erythroid cells. Blood, 2005, 105, 4170-4178.	1.4	103
22	Overexpression of the Anti-Adhesin Podocalyxin Is an Independent Predictor of Breast Cancer Progression. Cancer Research, 2004, 64, 5068-5073.	0.9	136
23	Avian Models to Study the Transcriptional Control of Hematopoietic Lineage Commitment and to Identify Lineage-Specific Genes. Cells Tissues Organs, 2002, 171, 44-63.	2.3	14